Nov
2001

Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis.

Goicoechea M, Caramelo C, Rodriguez P, et al.
Nephrol Dial Transplant 2001;16(11):2188-2193.
NATA Rating :
NATA Review
This is a very interesting point that is probably unknown to many clinicians. Personally, I was not aware of this problem. These findings remain to be explained. Why should anti-platelet agents influence EPO and iron dosages? Higher iron dosages in PTFE graft patients could simply be a consequence of higher EPO dosages.

– C. Breymann.